$MDT

The FDA issued a safety alert for Medtronic's Bravo CF capsule delivery devices, reporting 184 serious injuries due to a failure in capsule attachment or detachment. The alert covers unused inventory with expiration dates on or before October 20, 2027. Medtronic has recalled affected lots and is replacing them. Patients scheduled for reflux testing should verify their clinic's inventory.

The FDA issued an early alert regarding Medtronic's esophageal pH monitoring capsule delivery device, citing potential issues. The alert aims to inform healthcare providers and patients about the concerns.

Medtronic recalled 135,875 units of its V-Loc 90 Absorbable Wound Closure Device due to potential tears in sterile packaging, risking biocontamination. The FDA classified this as a Class 2 recall, and hospitals are advised to monitor patients treated with affected sutures for infections or vision issues. The recall spans 11 product codes and multiple countries, with distribution ongoing since July. No injuries have been reported, but patients with symptoms should contact their surgical teams.

Medtronic (MDT), a medical device maker, has underperformed over the past five years, with a 33% stock decline. Despite challenges, it trades at 15x forward earnings with a 3.4% yield and is on track to join the Dividend Kings. Analysts expect revenue and EPS growth, driven by new products and AI integration, with a median price target of $100. The company's restructuring and strong cash flow make it a potential value play.

Medtronic's board approved a $0.72 per share cash dividend for Q2 fiscal year 2027, payable October 16, 2026. This matches the increased dividend announced in June 2026. The company has raised its annual dividend for 49 consecutive years. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index.

Medtronic (MDT) and Thermo Fisher (TMO) are healthcare companies with different recovery drivers. MDT reported its highest annual revenue growth in a decade, with strong performance in its cardiac segment. TMO's recovery is tied to improving customer spending in life sciences. Both companies are investing in growth areas.

Danaher (DHR) and Medtronic (MDT) report recovery signs. DHR benefits from life sciences demand, with bioprocessing orders growing mid-teens. MDT shows highest annual revenue growth in 10 years, with Q4 revenue at $9.8B and FY26 at $36.4B. MDT's cardiac segment grew 78% globally, driven by cardiac ablation solutions. Both companies face challenges, with MDT's growth concentrated in a few platforms and DHR's revenue delayed into next year.

Medtronic (MDT) and Tenet Healthcare (THC) present distinct growth prospects. MDT reported its highest annual revenue growth in a decade, driven by cardiac ablation solutions and investments in innovation. THC saw a 52.2% increase in adjusted EPS and 6.8% revenue growth, with margin expansion in hospitals. Investors must choose between MDT's innovation-led recovery and THC's operational improvements.

Medtronic plc (NYSE: MDT) declared a $0.72 per share cash dividend for Q2 fiscal 2027, payable October 16, 2026. This matches the increased dividend announced in June 2026. The company has raised its annual dividend for 49 consecutive years. Medtronic is a global healthcare technology firm with a portfolio of medical devices and therapies.

Medtronic announced a quarterly dividend of $0.72 per share, payable on October 16 to shareholders of record on September 25. The company's stock has seen a 5-day change of -1.94% and a year-to-date change of +1.90%.